GlassScriptPhysician profile
Paul Mckinley
NPI 1578652418
$915.98
in general payments reported to CMS, 2019-2025
11 companies · $62.19 in 2025
The $62.19 reported for 2025 was less than what a typical Sports Medicine (Family Medicine) provider received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $333 · 2022: $86.57 · 2023: $219 · 2024: $215 · 2025: $62.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $496.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $440.47 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $136.28 | 2019-2023 | Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.19 | 2019 | |
| Exact Sciences Corporation | $57.21 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $31.40 | 2022-2023 | Quviviq |
| Dexcom, INC. | $29.79 | 2019 | |
| Janssen Biotech, INC. | $28.83 | 2019 | |
| Merz North America, INC. | $24.61 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $17.58 | 2024 | Rexulti |
| Antares Pharma, INC. | $14.51 | 2022 | |
| Integra Lifesciences Corporation | $14.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Mckinley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.